Jill Conway, MD
Neurology · Charlotte, NCNPI 1205991502
Payments from drug & device makers
Across 945 payments — averaging $1667.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$417K
- Sanofi$251K
- AstraZeneca$242K
- F. Hoffmann-la Roche AG$172K
- Genentech USA, Inc.$157K
- EMD Serono, Inc.$143K
- plus $194K from 13 others
Across 6 payments — averaging $86.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$522
What the payments were for
- Consulting fees$178,18618%
- Speaking & faculty fees$721,26772%
- Travel & lodging$84,9948%
- Food & beverage$17,6402%
- Education$2100%
- Gifts$2,7330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 95 | $416,769 |
| Sanofi | 232 | $250,959 |
| AstraZeneca | 217 | $242,102 |
| F. Hoffmann-la Roche AG | 9 | $172,407 |
| Genentech USA, Inc. | 117 | $156,642 |
| EMD Serono, Inc. | 126 | $142,544 |
| Amgen(2 entities) | 76 | $88,460 |
| Roche Products Limited | 12 | $50,267 |
| Bristol Myers Squibb | 24 | $16,204 |
| Adamas Pharmaceuticals, Inc. | 7 | $14,189 |
| TG Therapeutics, Inc. | 12 | $9,010 |
| E.r. Squibb & Sons, L.L.C. | 6 | $7,760 |
| Greenwich Biosciences, Inc. | 1 | $3,570 |
| Biogen | 2 | $2,316 |
| Johnson & Johnson | 1 | $1,320 |
| Bayer | 3 | $849 |
| Sanofi-aventis U.S. LLC | 2 | $124 |
| AbbVie | 1 | $92 |
| Genentech, Inc. | 2 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,575,664 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 67 | $570,147 |
| Glatiramer Acetate | 17 | $44,768 |
| Dimethyl Fumarate | 20 | $27,174 |
| Dalfampridine ErDalfampridine | 38 | $7,501 |
| Gabapentin | 124 | $2,647 |
| Baclofen | 135 | $2,637 |
| FingolimodFingolimod Hcl | 11 | $2,318 |
| Teriflunomide | 35 | $1,529 |
| Modafinil | 21 | $1,137 |
| Tizanidine Hcl | 24 | $802 |
| Solifenacin Succinate | 12 | $604 |
| Duloxetine Hcl | 23 | $454 |
| Pregabalin | 18 | $415 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $254 |
| Sertraline Hcl | 17 | $145 |
Paid to pharmacies, not to this prescriber.
Other neurology in Charlotte
- Mohammad BolouriCharlotte$16.6M
- T RaoCharlotte$4M
- Donna GravesCharlotte$1.8M
- Matthew CarraroCharlotte$1.5M
- Urvi DesaiCharlotte$937K
- Ardith CourtneyCharlotte$862K
- Sanjay IyerCharlotte$685K
- Megan DonnellyCharlotte$601K
- Kenneth AshkinCharlotte$525K
- Leo McCluskeyCharlotte$286K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.